@article { author = {IBRAHIM, SHEREEN and MOHAMED, SABAH and FOAAD, HEBA and AHMAD, HAYTHAM and AL-GHANDOUR, ASMAA}, title = {EFFICACY OF MURINE PLATELET RICH-PLASMA VERSUS SPIRAMYCIN IN TREATMENT OF CHRONIC TOXOPLASMOSIS INFECTED MICE}, journal = {Journal of the Egyptian Society of Parasitology}, volume = {52}, number = {2}, pages = {267-278}, year = {2022}, publisher = {The Egyptian Society of Parasitology}, issn = {1110-0583}, eissn = {2090-2549}, doi = {10.21608/jesp.2022.257455}, abstract = {Apicomplexan parasite, Toxoplasma gondii, is an obligate intracellular parasite, infectingand replicating within nucleated cells in many homoeothermic organisms, mammals and birdswith the possibility of causing serious health problems. Recent studies indicated several sideeffects to the current drugs like Pyrimethamine® & Sulfadiazine®. This work evaluated murineplatelet rich plasma (PRP) efficacy versus Spiramycin® treating toxoplasmosis infectedmice parasitological, biochemical and histopathological studies. Fifty five immunocompetentmale mice were divided into 5 groups of 11 mice each. G1: non-infected control, G2: infectednon-treated control, G3: infected and treated with spiramycin, G4: infected and treated withmurine PRP, and G5: infected and treated with combined spiramycin and PRP.Spiramycin and PRP treated mice gave the highest reduction in Toxoplasma tissue cysts number,lowest level of serum malondialdehyde (MDA) and marked pathological improvement.}, keywords = {Mice,toxoplasma gondii,platelet rich plasma,Spiramycin,Malondialdehyde}, url = {https://jesp.journals.ekb.eg/article_257455.html}, eprint = {https://jesp.journals.ekb.eg/article_257455_9538434b7d14c1a1abc024b982ef1d84.pdf} }